Burkat P
J Psychopharmacol. 2025; 39(3):244-253.
PMID: 39754528
PMC: 11843794.
DOI: 10.1177/02698811241309620.
Su Y, Cao C, Chen S, Lian J, Han M, Liu X
Biomedicines. 2024; 12(7).
PMID: 39061977
PMC: 11274235.
DOI: 10.3390/biomedicines12071403.
Bampali K, Koniuszewski F, Silva L, Rehman S, Vogel F, Seidel T
Br J Pharmacol. 2022; 179(14):3675-3692.
PMID: 35088415
PMC: 9314015.
DOI: 10.1111/bph.15807.
Theriault R, St-Denis M, Hewitt T, Khokhar J, Lalonde J, Perreault M
Int J Mol Sci. 2021; 22(11).
PMID: 34073710
PMC: 8197248.
DOI: 10.3390/ijms22115511.
Wong Y, Centanni M, de Lange E
J Clin Pharmacol. 2019; 59(5):731-747.
PMID: 30676661
PMC: 6590357.
DOI: 10.1002/jcph.1365.
Neural Responsivity to Food Cues in Patients With Unmedicated First-Episode Psychosis.
Borgan F, ODaly O, Hoang K, Veronese M, Withers D, Batterham R
JAMA Netw Open. 2019; 2(1):e186893.
PMID: 30646204
PMC: 6420094.
DOI: 10.1001/jamanetworkopen.2018.6893.
Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis.
Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G
Schizophr Bull. 2017; 43(4):862-871.
PMID: 28044008
PMC: 5472156.
DOI: 10.1093/schbul/sbw171.
Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits.
Sebel L, Graves S, Chan C, Surmeier D
Neuropsychopharmacology. 2016; 42(4):963-973.
PMID: 27577602
PMC: 5312058.
DOI: 10.1038/npp.2016.173.
Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [C]DASB PK-PD Study.
Kim E, Howes O, Kim B, Chon M, Seo S, Turkheimer F
Clin Pharmacokinet. 2016; 56(4):371-381.
PMID: 27557550
DOI: 10.1007/s40262-016-0444-x.
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms.
Li M
J Psychopharmacol. 2016; 30(8):749-70.
PMID: 27371498
PMC: 4944179.
DOI: 10.1177/0269881116654697.
A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development.
Spiros A, Geerts H
J Exp Pharmacol. 2016; 4:53-61.
PMID: 27186116
PMC: 4863548.
DOI: 10.2147/JEP.S30808.
In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.
Loryan I, Melander E, Svensson M, Payan M, Konig F, Jansson B
Mol Psychiatry. 2016; 21(11):1527-1536.
PMID: 26809840
DOI: 10.1038/mp.2015.229.
Successful management of clozapine adverse effects with extended (alternate day) antipsychotic dosing in a patient with schizophrenia.
Kumar V, Sharma L, Madival S, Venkatasubramanian G
J Psychiatry Neurosci. 2015; 41(1):E1-2.
PMID: 26674512
PMC: 4688032.
DOI: 10.1503/jpn.150132.
The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J
CNS Drugs. 2015; 29(8):637-58.
PMID: 26293744
DOI: 10.1007/s40263-015-0269-4.
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Karpel-Massler G, Kast R, Westhoff M, Dwucet A, Welscher N, Nonnenmacher L
J Neurooncol. 2014; 122(1):21-33.
PMID: 25524815
DOI: 10.1007/s11060-014-1688-7.
Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.
Lian J, Huang X, Pai N, Deng C
PLoS One. 2014; 9(8):e104160.
PMID: 25084453
PMC: 4118967.
DOI: 10.1371/journal.pone.0104160.
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
Pagsberg A, Jeppesen P, Klauber D, Gjessing Jensen K, Ruda D, Stentebjerg-Olesen M
BMC Psychiatry. 2014; 14:199.
PMID: 25015535
PMC: 4227115.
DOI: 10.1186/1471-244X-14-199.
Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis.
Mousavi S, Rostami H, Sharbafchi M, Boroujeni A, Mahaki B
J Res Pharm Pract. 2014; 2(4):138-44.
PMID: 24991622
PMC: 4076925.
DOI: 10.4103/2279-042X.128142.
The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study.
Kurita M, Nishino S, Numata Y, Okubo Y, Sato T
PLoS One. 2014; 9(6):e100634.
PMID: 24971450
PMC: 4074114.
DOI: 10.1371/journal.pone.0100634.
Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.
Bonoldi I, Howes O
CNS Drugs. 2014; 28(7):649-63.
PMID: 24919790
DOI: 10.1007/s40263-014-0177-z.